- 英文名称
- Notoginsenoside Fc
- 分子式
- C58H98O26
- 分子量
- 1211.38
- 中文别名
- 三七皂苷 Fc; 三七皂苷FC标准品; 三七皂苷FC对照品; 三七皂苷FC/萜类; (2S,3R,4S,5S,6R)-2-(((S)-2-((3S,5R,8R,9R,10R,12R,13R,14R,17S)-3-(((2R,3R,4S,5S,6R)-3-(((2S,3R,4S,5S,6R)-4,5-二羟基-6-(羟甲基)-3-(((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2-基)氧基)四氢-2H-吡喃-2-基)氧基)-4,5-二羟基-6-(羟甲基)四氢-2H-吡喃-2-基)氧基)-12-羟基-4,4,8,10,14-五甲基十六氢-1H-环戊并[a]菲-17-基)-6-甲基庚-5-烯-2-基)氧基)-6-((((2S,3R,4S,5R)-3,4,5-三羟基四氢-2H-吡喃-2-基)氧基)甲基)四氢-2H-吡喃-3,4,5-三醇; (2S,3R,4S,5S,6R)-2-(((S)-2-((3S,5R,8R,9R,10R,12R,13R,14R,17S)-3-(((2R,3R,4S,5S,6R)-3-(((2S,3R,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-12-hydroxy-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-methylhept-5-en-2-yl)oxy)-6-((((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3,4,5-triol; β-D-Glucopyranoside, (3β,12β)-12-hydroxy-20-[(6-O-β-D-xylopyranosyl-β-D-glucopyranosyl)oxy]dammar-24-en-3-yl O-β-D-xylopyranosyl-(1→2)-O-β-D-glucopyranosyl-(1→2); Dammarane, β-D-glucopyranoside deriv.; (3β,12β)-12-Hydroxy-20-{[6-O-(β-D-xylopyranosyl)-β-D-glucopyranosyl]oxy}dammar-24-en-3-yl β-D-xylopyranosyl-(1->2)-β-D-glucopyranosyl-(1->2)-β-D-glucopyranoside; NotoginsenosideFc; Notoginseng saponin FC
- 用途
- 中草药成分，具有良好的抗血小板凝集作用；可通过促进自噬促进糖尿病大鼠血管损伤后的内皮细胞再生；体外研究中，20μM作用24小时可显著上调RAOECs中LC3B和Beclin 1的表达，下调p62的表达；体内研究中，3.5mg/kg/天可加速糖尿病Sprague-Dawley大鼠颈动脉损伤后的内皮再生，减轻过度新生内膜形成；用于含量测定、鉴定、药理实验等生命科学研究。
